Maggie Fox | 29 Sep 2023 | Reuters
The numbers were so bad that Dr. Stephen Hoffman did not even want to say them out loud. "It was a low number," he said. Pressed, he added, "Only a handful." Finally he squeezed the numbers out. "We had five."
Maggie Koerth-Baker | 23 Apr 2023 | National Geographic
Important research into discovering a vaccine and/or the development of genetically modified malaria-fighting mosquitoes is constantly evolving and making important steps forward.
Maggie Fox | 08 Dec 2023 | Reuters
An experimental malaria vaccine is the most promising yet, protecting up to 65 percent of infants from infection in two studies in Africa, researchers reported on Monday.
Tamar Kahn | 11 Nov 2023 | Business Day (South Africa)
Scientists hoped to start final tests on the world's most
advanced malaria vaccine early next year, they said yesterday.
Albert Muriuki | 24 Mar 2024 | Business Daily (Nairobi)
The war against malaria, a leading global killer, has moved a notch higher with the announcement of successful clinical trials of a vaccine for children - the group that is most vulnerable to the disease.
Staff Writers | 28 Jan 2024 | East African Standard
Researchers at the National Institute for Medical Research (NIMR) in Tanga Region of Tanzania are carrying out a clinical trial to evaluate the safety and immunological potential of a candidate malaria vaccine called MSP3-LSP.
Staff Writers | 24 Jan 2024 | Agence France Presse
A small trial of a malaria vaccine in Mali showed promising results, according to results published in the United States.
Staff Writers | 24 Jan 2024 | Washington Post
A new malaria vaccine looked strong in a small trial conducted in Mali by a team of international researchers. The vaccine -- designed to prevent the malaria parasite from entering blood cells -- was safe and provoked strong immune responses (up to a sixfold increase in vaccine-specific antibodies) in the 40 adults who received it, according to the 17-member research team, based at the Malaria Research and Training Center at the University of Bamako.
Maame Efua Moses | 14 Dec 2023 | Accra Daily Mail
Fifteen months after the first trial of the phase 2 (Mal 47) of the RTS'S malaria vaccine was administered to children in the Kintampo North and South Districts, ADM can confirm that most of these children are looking healthy and strong. Lawrence Gyabaa, Assistant Research Officer, KHRC who has done a study on the Mal 47 told ADM that the primary objective of his study was to investigate how community members perceived malaria prevention through the use of vaccines. He explained that the RTS,S malaria vaccine was created in 1987 and has been developed by GlaxoSmithKline (GSK) Biological in close collaboration with Walter Reed Army Institute of Research in the USA.
Maame Efua Moses | 14 Dec 2023 | Accra Daily Mail
Fifteen months after the first trial of the phase 2 (Mal 47) of the RTS'S malaria vaccine was administered to children in the Kintampo North and South Districts, ADM can confirm that most of these children are looking healthy and strong.